VantEdge Access helps biopharma teams secure reimbursement, strengthen pricing strategy, and anticipate HTA outcomes, through senior-led consulting and three proprietary platforms: OMNIA, PreserveIQ and MFN PRICE.
Evidence-driven. Payer-aligned. Launch-ready.
Senior market access leadership
Pricing, reimbursement, and HEOR expertise
Rare disease and specialty access focus
AI-enabled HTA intelligence across global markets
We start where payers start.
We assess evidence through the lens of HTA decision-making, reimbursement constraints, and stakeholder incentives—then design strategies that hold up across markets.
No layers. No handoffs. Direct access leadership.
Evidence and positioning built around what payers reward.
Clinical development, HEOR, pricing, and access—connected.
OMNIA accelerates analogue intelligence and HTA learning.
Access is strategy.
We help teams treat access planning as a strategic advantage—not a late-stage obstacle.
Speak With Our TeamIncorporated in Illinois with hubs in Chicago/Oak Brook (US) and Paris (FR), VantEdge Access combines proprietary AI with deep consulting expertise across the USA*, Canada, EU-5 and other international markets**, leveraging one of the industry's largest HTA databases with 10,000+ reports and 1,200+ drugs covering all therapeutic areas.
Global and local strategies that align evidence, stakeholders, and reimbursement realities.
Defensible pricing corridors grounded in HTA logic and analogue outcomes.
OMNIA, PreserveIQ and MFN PRICE: evidence, recovery and pricing exposure, connected to enterprise value.
Proprietary platforms
Human intelligence, augmented by three purpose-built tools. OMNIA reads the HTA landscape, PreserveIQ recovers value after a negative decision, and MFN PRICE quantifies pricing exposure across markets. Each stands alone; together they connect evidence, recovery and pricing to enterprise value.
10,000+
HTA reports
10
National agencies
1,200+
Drugs, all therapeutic areas
3
Proprietary platforms
HTA intelligence engine
Source-linked answers from 10,000+ HTA reports across ten national agencies, with analogue sets, an agentic assistant and a JCA readiness scorecard.
Delivers
Applies when
Value preservation framework
A negative decision creates immediate pressure to discount. PreserveIQ diagnoses what blocked reimbursement, tests whether price can solve it, and sequences the response.
Delivers
Applies when
Pricing exposure framework
Most Favored Nation pricing is not one price, it is cross-market transmission. Exposure is scored alongside strategic flexibility, before the launch sequence is fixed.
Delivers
Applies when
01
OMNIA supplies the precedent: what payers accepted, refused and negotiated.
02
PreserveIQ and MFN PRICE turn it into a recovery posture and a defensible pricing position.
03
Both answer one question: what the decision is worth to the company.
Stronger payer positioning earlier in development
Faster access planning and launch readiness
More confident pricing and negotiation strategy
Improved alignment across access, medical, and commercial teams
Reduced reimbursement risk across markets
Focused engagements built around the decisions that determine reimbursement outcomes.
Align your clinical development strategy with payer expectations before it becomes expensive to change.
Define pricing corridors that reflect real-world HTA logic and analogue outcomes.
Evidence packages built to withstand HTA review and reimbursement scrutiny.
Structured market access roadmaps across markets and stakeholders.
Identify access barriers early. Prioritize them. Solve them.
Faster insights. Better strategy. Stronger execution.
Turn a negative, restricted or delayed decision into a managed recovery.
Score cross-market pricing exposure before the launch sequence is fixed.
Need clarity on your next access milestone?
Request a ConsultationVantEdge Access is led by market access professionals who have shaped strategy across major pharma, biotech, and specialty markets.
CEO & Co-Founder
Market access executive, strategist, author, and international speaker with deep expertise across pricing, reimbursement, HEOR, and payer engagement.
Well‑published, including the authoritative book Frontiers in Market Access and as contributing author in Development of Gene Therapies. Excels in corporate strategy and high‑level stakeholder engagement, ensuring innovative treatments reach patients across diverse market archetypes.
CTO & Co-Founder
AI and analytics leader specializing in market access intelligence, platform development, and strategic decision support.
Educated at Columbia University (Master's in Management Science) and École des Ponts ParisTech (Diplôme d'Ingénieur, Finance). Founder of Access Explorer, he spearheads AI‑driven analytics to transform market‑access consulting worldwide.
Small team. Senior attention. High-impact delivery.
We are built for speed, precision, and accountability.
Work With Us
Commercial Strategy Advisor
Sarah is a seasoned healthcare executive with over 20 years of commercial operations leadership in the pharmaceutical and biotechnology industry. She is Chief Commercial Officer at uMETHOD, a company that uses AI to improve healthcare delivery. Previously, she was Chief Commercial Officer at 9Meters Biopharma, a publicly held biotech focused on rare gastrointestinal diseases.
Prior to 9Meters, Ms. Liu was Vice President of Global Marketing and Vice President of New Product Planning at Novartis Gene Therapies. Earlier in her career, she held senior commercial leadership roles at Melinta Therapeutics, Takeda, and Abbott. Sarah earned an MBA from Wharton and a BA from Northwestern University.
Oncology Strategy Advisor
Kimary Kulig's professional career spans academic, non-profit, large pharma, and biotech start-up ecosystems. Owner and Principal of Kulig Consulting, she provides advice and services to companies developing oncology products. Additionally, she offers professional navigation services to cancer patients as My Biomarker Navigator®.
Kimary applied her unique training in immunology, molecular oncology, and epidemiology for 22 years at both Pfizer and Bristol Myers Squibb, between which she was Vice President at the National Comprehensive Cancer Network (NCCN) overseeing all operations of its Outcomes Research Database.
As Head of Oncology Clinical Research at Verily Life Sciences (Google), Kimary led digital pathology AI algorithm development. Kimary received her PhD from New York University's Institute of Graduate Biomedical Sciences and her MPH from Columbia University's Mailman School of Public Health.
Whether you're shaping early development strategy, preparing for launch, or strengthening reimbursement positioning—we can help.
Oak Brook, Illinois
Start with a strategy call.
Or leave your details and we'll reach out
